Rick Pazdur (via AACR)
FDA's oncology head Rick Pazdur defends the accelerated approval pathway, claiming it is 'under attack'
The FDA is sounding the alarm over its accelerated approval pathway as backlash continues over the recent nod in favor of Biogen’s Alzheimer’s drug Aduhelm …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
